OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 302,369 Shares of Stock

Key Points

• Director David Pelizzon sold 302,369 OrthoPediatrics shares at an average price of $21.01, generating approximately $6.35 million. The sale reduced his stake by 4.65%, leaving him with 6.20 million shares.
• OrthoPediatrics reported quarterly revenue of $70.51 million and an adjusted loss of $0.26 per share, beating analyst estimates for both revenue and EPS.
• Analysts maintain a generally positive outlook, with nine Buy ratings, one Hold and one Sell; the stock has a “Moderate Buy” consensus rating and a $26.44 average price target.

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) Director David Pelizzon sold 302,369 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the sale, the director owned 6,201,764 shares of the company's stock, valued at $130,299,061.64. This trade represents a 4.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

OrthoPediatrics Price Performance

Shares of NASDAQ KIDS traded down $0.12 during mid-day trading on Thursday, reaching $21.56. The company had a trading volume of 492,212 shares, compared to its average volume of 174,613. The company has a 50-day moving average price of $21.94 and a two-hundred day moving average price of $18.99. The stock has a market cap of $562.93 million, a PE ratio of -12.83 and a beta of 0.99. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. OrthoPediatrics Corp. has a 1-year low of $14.42 and a 1-year high of $26.74.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The business had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. On average, equities analysts anticipate that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KIDS has been the subject of several research analyst reports. Needham & Company LLC upped their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, August 5th. Piper Sandler reissued an "overweight" rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Truist Financial set a $22.00 target price on OrthoPediatrics in a report on Wednesday, August 5th. Finally, BTIG Research lifted their price target on OrthoPediatrics from $24.00 to $29.00 and gave the company a "buy" rating in a report on Thursday, August 20th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, OrthoPediatrics currently has an average rating of "Moderate Buy" and a consensus target price of $26.44.

Hedge Funds Weigh In On OrthoPediatrics

Several institutional investors and hedge funds have recently modified their holdings of KIDS. AIGH Capital Management LLC acquired a new position in OrthoPediatrics in the 2nd quarter worth about $5,161,000. Wasatch Advisors LP grew its stake in shares of OrthoPediatrics by 56.6% in the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company's stock valued at $9,865,000 after buying an additional 186,357 shares in the last quarter. Roubaix Capital LLC grew its stake in shares of OrthoPediatrics by 23.8% in the 1st quarter. Roubaix Capital LLC now owns 290,047 shares of the company's stock valued at $4,603,000 after buying an additional 55,724 shares in the last quarter. BlackRock Inc. acquired a new position in OrthoPediatrics in the second quarter worth approximately $24,347,000. Finally, Granahan Investment Management LLC increased its holdings in OrthoPediatrics by 35.1% in the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company's stock worth $14,231,000 after buying an additional 232,760 shares during the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.